Antiobesity Effect of Eicosapentaenoic Acid in High-Fat/High-Sucrose Diet–Induced Obesity
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Given the pleiotropic effect of eicosapentaenoic acid (EPA), it is interesting to know whether EPA is capable of improving obesity. Here we examined the anti-obesity effect of EPA in mice with two distinct models of obesity. RESEARCH DESIGN AND METHODS: Male C57BL/6J mice were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5% [w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat, 8.5% [w/w] sucrose) (HF group) for 4–20 weeks. A total of 5% EPA was administered by partially substituting EPA for fat in the HF/HS + EPA and HF + EPA groups. RESULTS: Both the HF/HS and HF groups similarly developed obesity. EPA treatment strongly suppresses body weight gain and obesity-related hyperglycemia and hyperinsulinemia in HF/HS-fed mice (HF/HS + EPA group), where hepatic triglyceride content and lipogenic enzymes are increased. There is no appreciable effect of EPA on body weight in HF-fed mice (HF + EPA group) without enhanced expression of hepatic lipogenic enzymes. Moreover, EPA is capable of reducing hepatic triglyceride secretion and changing VLDL fatty acid composition in the HF/HS group. By indirect calorimetry analysis, we also found that EPA is capable of increasing energy consumption in the HF/HS + EPA group. CONCLUSIONS: This study is the first demonstration that the anti-obesity effect of EPA in HF/HS-induced obesity is associated with the suppression of hepatic lipogenesis and steatosis. Because the metabolic syndrome is often associated with hepatic lipogenesis and steatosis, the data suggest that EPA is suited for treatment of the metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“Enhanced hepatic lipogenesis and hepatic steatosis also appear to play an important role in the pathogenesis of the metabolic syndrome (3).”
BackgroundTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Unsaturated Fatty Acids Down-regulate SREBP Isoforms 1a and 1c by Two Mechanisms in HEK-293 Cells
Hannah, V. C., Ou, J., Luong, A., Goldstein, J. L., & Brown, M. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007273200 · Cited by 448 · cited 1×
“Cytoplasmic and nuclear proteins were extracted as described (24,25) with slight modifications.”
MethodPolyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression
Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J.-I., Yamada, N., & Shimano, H. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.028 · Cited by 415
Abu-Elheiga, L., Oh, W., Kordari, P., & Wakil, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733877100 · Cited by 389
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316 · cited 2×
“In a recent sub-analysis of the JELIS, EPA had a great risk reduction of coronary artery events of 53% in patients with high triglycerides and low HDL cholesterol (11), suggesting that EPA may be effective to reduce the incidence of atherosclerosis in the metabolic syndrome.”
BackgroundKuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1305-z · Cited by 142 · cited 1×
“(46) reported that treatment with fish oil tends to prevent HF-induced body weight gain, although not with statistical significance.”
BackgroundProtection From Obesity in Mice Lacking the VLDL Receptor
Goudriaan, J. R., Tacken, P. J., Dahlmans, V. E. H., Gijbels, M. J. J., van Dijk, K. W., Havekes, L. M., & Jong, M. C. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.095147 · Cited by 133
Yamada, H., Yoshida, M., Nakano, Y., Suganami, T., Satoh, N., Mita, T., Azuma, K., Itoh, M., Yamamoto, Y., Kamei, Y., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171736 · Cited by 112 · cited 1×
“Eicosapentaenoic acid (EPA), one of the major n-3 PUFAs contained in fish oil, has a variety of pharmacological effects such as lipid-lowering (5), anti-platelet (6), anti-inflammatory (7), and anti-atherogenic effects (8,9).”
BackgroundSelf-citation
Cited by
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
Rodent Models for Metabolic Syndrome Research
Panchal, S. K., & Brown, L. (2011) · BioMed Research International · doi:10.1155/2011/351982 · Cited by 408
Omega-3 fatty acids in obesity and metabolic syndrome: A mechanistic update
Albracht-Schulte, K., Kalupahana, N. S., Ramalingam, L., Wang, S., Rahman, S. M., Robert-McComb, J., & Moustaid-Moussa, N. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.012 · Cited by 355
“Omega-3 PUFAs reduce lipogenesis and reduce hepatic VLDL secretion [51].”
BackgroundOmega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-analysis
Wu, J. H. Y., Micha, R., Imamura, F., Pan, A., Biggs, M. L., Ajaz, O., Djousse, L., B. Hu, F., & Mozaffarian, D. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001602 · Cited by 340
Rossmeisl, M., Macek Jilkova, Z., Kuda, O., Jelenik, T., Medrikova, D., Stankova, B., Kristinsson, B., Haraldsson, G. G., Svensen, H., Stoknes, I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038834 · Cited by 230
“Moreover, conflicting data exist regarding the potential role of dietary macronutrient composition in the anti-obesity effects of LC n-3 PUFA [56,57].”
Background
Metadata
- Authors
- Sato, A., Kawano, H., Notsu, T., Ohta, M., Nakakuki, M., Mizuguchi, K., Itoh, M., Suganami, T., & Ogawa, Y.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-08-03
- Volume
- 59
- Issue
- 10
- Pages
- 2495-2504
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2127832205
- Cited by
- 162
- References
- 11
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.